Paclitaxel liposome encapsulated - INSYS Therapeutics
Alternative Names: LEP; LEP-ETU; Liposome encapsulated paclitaxel; Liposome entrapped paclitaxel; NeoLipid™ paclitaxel; ONC 0355; Paclitaxel liposomal - INSYS Therapeutics; PNU 914; PNU 93914Latest Information Update: 15 Jan 2022
At a glance
- Originator Georgetown University
- Developer INSYS Therapeutics, Inc
- Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer; Cervical cancer; Cholangiocarcinoma; Gastric cancer; Ovarian cancer
Most Recent Events
- 28 May 2018 No recent reports of development identified for preclinical development in Gastric-cancer in USA (IV)
- 28 May 2018 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (IV)
- 18 Oct 2016 Phase-II clinical trials in Cervical cancer in USA (IV) (INSYS Therapeutics pipeline October 2016)